KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Quest Diagnostics (DGX) Consolidated Net Income (2017 - 2025)

Quest Diagnostics' Consolidated Net Income history spans 15 years, with the latest figure at $249.0 million for Q4 2025.

  • For Q4 2025, Consolidated Net Income rose 7.79% year-over-year to $249.0 million; the TTM value through Dec 2025 reached $1.0 billion, up 11.31%, while the annual FY2025 figure was $1.0 billion, 11.31% up from the prior year.
  • Consolidated Net Income for Q4 2025 was $249.0 million at Quest Diagnostics, down from $251.0 million in the prior quarter.
  • Across five years, Consolidated Net Income topped out at $762.0 million in Q2 2021 and bottomed at $113.0 million in Q4 2022.
  • The 5-year median for Consolidated Net Income is $244.0 million (2022), against an average of $288.0 million.
  • The largest annual shift saw Consolidated Net Income tumbled 67.72% in 2022 before it skyrocketed 74.34% in 2023.
  • A 5-year view of Consolidated Net Income shows it stood at $266.0 million in 2021, then plummeted by 57.52% to $113.0 million in 2022, then surged by 74.34% to $197.0 million in 2023, then increased by 17.26% to $231.0 million in 2024, then grew by 7.79% to $249.0 million in 2025.
  • Per Business Quant, the three most recent readings for DGX's Consolidated Net Income are $249.0 million (Q4 2025), $251.0 million (Q3 2025), and $287.0 million (Q2 2025).